Treatment with obinutuzumab leads to worse outcomes in haematological patients diagnosed with Omicron variant COVID-19.
作者信息
Shafat Tali, Grupel Daniel, Porges Tzvika, Levi Itai, Yagel Yael, Nesher Lior
机构信息
Infectious Diseases Institute, Soroka University Medical Center, and the faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Clinical Research Center, Soroka University Medical Center, and the faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
出版信息
Br J Haematol. 2022 Sep;198(5):826-829. doi: 10.1111/bjh.18315. Epub 2022 Jun 19.
Abstract
摘要
相似文献
1
Treatment with obinutuzumab leads to worse outcomes in haematological patients diagnosed with Omicron variant COVID-19.
Br J Haematol. 2022 Sep;198(5):826-829. doi: 10.1111/bjh.18315. Epub 2022 Jun 19.
2
Outcomes of COVID-19 in patients with obinutuzumab compared with patients with rituximab: a retrospective cohort study.
Virol J. 2024 Sep 9;21(1):212. doi: 10.1186/s12985-024-02484-x.
3
An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab.
Cancer Med. 2024 Feb;13(3):e6997. doi: 10.1002/cam4.6997.
4
Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.
J Med Virol. 2022 Oct;94(10):5038-5043. doi: 10.1002/jmv.27916. Epub 2022 Jun 11.
5
Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.
J Infect Chemother. 2022 Jul;28(7):991-994. doi: 10.1016/j.jiac.2022.03.002. Epub 2022 Mar 23.
6
[Sotrovimab in controlling SARS-CoV-2 infection].
Pol Merkur Lekarski. 2022 Feb 22;50(295):48-50.
7
Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab.
Clin Microbiol Infect. 2022 Sep;28(9):1297-1299. doi: 10.1016/j.cmi.2022.05.002. Epub 2022 May 17.
8
Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.
Elife. 2022 Nov 22;11:e79639. doi: 10.7554/eLife.79639.
9
Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses.
Front Immunol. 2022 Jul 25;13:897748. doi: 10.3389/fimmu.2022.897748. eCollection 2022.
10
Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients.
Lancet Microbe. 2022 Aug;3(8):e559. doi: 10.1016/S2666-5247(22)00120-3. Epub 2022 May 27.
引用本文的文献
1
Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study.
Infect Dis Ther. 2025 Jan;14(1):167-180. doi: 10.1007/s40121-024-01089-9. Epub 2024 Dec 9.
2
Obinutuzumab treatment for membranous nephropathy: effectiveness and safety concerns during the COVID-19 pandemic.
Clin Kidney J. 2024 Oct 4;17(11):sfae299. doi: 10.1093/ckj/sfae299. eCollection 2024 Nov.
3
In the SARS-CoV-2 era, do we need to be afraid of obinutuzumab?
Br J Haematol. 2024 Dec;205(6):2113-2115. doi: 10.1111/bjh.19786. Epub 2024 Sep 27.
4
Outcomes of COVID-19 in patients with obinutuzumab compared with patients with rituximab: a retrospective cohort study.
Virol J. 2024 Sep 9;21(1):212. doi: 10.1186/s12985-024-02484-x.
5
Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma.
Br J Haematol. 2024 Dec;205(6):2219-2227. doi: 10.1111/bjh.19661. Epub 2024 Jul 22.
6
Caution to psychiatry ward: COVID-19 pneumonia can manifest weeks or months after testing positive with a PCR test in individuals on preexisting immune-suppressing medication.
PCN Rep. 2023 Aug 27;2(3):e135. doi: 10.1002/pcn5.135. eCollection 2023 Sep.
7
Initial Efficacy of the COVID-19 mRNA Vaccine Booster and Subsequent Breakthrough Omicron Variant Infection in Patients with B-Cell Non-Hodgkin's Lymphoma: A Single-Center Cohort Study.
Viruses. 2024 Feb 21;16(3):328. doi: 10.3390/v16030328.
8
An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab.
Cancer Med. 2024 Feb;13(3):e6997. doi: 10.1002/cam4.6997.
9
Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era-A Study of KroHem, the Croatian Group for Hematologic Diseases.
Biomedicines. 2024 Jan 31;12(2):331. doi: 10.3390/biomedicines12020331.
10
Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes.
Front Cell Infect Microbiol. 2023 Oct 19;13:1207225. doi: 10.3389/fcimb.2023.1207225. eCollection 2023.
本文引用的文献
1
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).
J Hematol Oncol. 2021 Oct 14;14(1):168. doi: 10.1186/s13045-021-01177-0.
2
Incidence, Clinical Presentation, Relapses and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Patients Treated With Anti-CD20 Monoclonal Antibodies.
Clin Infect Dis. 2022 May 30;74(10):1786-1794. doi: 10.1093/cid/ciab700.
3
SARS-CoV-2 universal screening upon adult hospital admission in Southern Israel.
J Hosp Infect. 2021 Aug;114:167-170. doi: 10.1016/j.jhin.2021.04.026. Epub 2021 Apr 30.
4
Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease.
Rheumatol Int. 2020 Dec;40(12):2117-2118. doi: 10.1007/s00296-020-04715-0. Epub 2020 Oct 12.
5
Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
Br J Haematol. 2019 Feb;184(4):524-535. doi: 10.1111/bjh.15720. Epub 2018 Dec 21.
6
A tale of two antibodies: obinutuzumab versus rituximab.
Br J Haematol. 2018 Jul;182(1):29-45. doi: 10.1111/bjh.15232. Epub 2018 May 9.
7
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
N Engl J Med. 2017 Oct 5;377(14):1331-1344. doi: 10.1056/NEJMoa1614598.
8
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
Lancet. 2011 Jan 1;377(9759):42-51. doi: 10.1016/S0140-6736(10)62175-7. Epub 2010 Dec 20.
Zotero 插件